AcquisitionOther
GILEAD SCIENCES, INC. acquired CymaBay
Public deal record from 8-K. The source names the buyer and target, and terms are shown only when the filing or announcement discloses them.
Deal tape row
GILEAD SCIENCES, INC. -> CymaBay · $32.50
The addition of CymaBay's investigational lead product candidate, seladelpar for the treatment of primary biliary cholangitis (PBC) including pruritus, complements Gilead's existing liver portfolio and aligns with its long-standing commitment to bringing trans
Open source record (SEC) ↗